董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick Spangler | 男 | Director | 70 | 23.50万美元 | 4.42 | 2026-03-12 |
| Lynn Vos | 女 | Chairperson | 70 | 26.90万美元 | 7.26 | 2026-03-12 |
| James Lang | 男 | Director | 61 | 20.40万美元 | 39.93 | 2026-03-12 |
| Gregory D. Wasson | 男 | Director | 66 | 20.10万美元 | 5.72 | 2026-03-12 |
| Catherine M. Klema | -- | Director | -- | 22.80万美元 | 2.16 | 2026-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen L. Silvestro | 男 | Chief Executive Officer | 48 | 271.77万美元 | 21.72 | 2026-03-12 |
| Marion Odence Ford | 女 | General Legal & Administrative Officer | 61 | 未披露 | 未持股 | 2026-03-12 |
| Brendan Merrell | 男 | Chief Operating Officer | 41 | 未披露 | 未持股 | 2026-03-12 |
| Edward Stelmakh | 男 | Chief Financial & Strategy Officer | 60 | 152.42万美元 | 23.21 | 2026-03-12 |
| Theresa Greco | 女 | Chief Commercial Officer | 53 | 154.43万美元 | 7.29 | 2026-03-12 |
| Doug Besch | 男 | Chief Product & Technology Officer | 44 | 未披露 | 未持股 | 2026-03-12 |
| Andrew D Silva | 男 | Chief Business Officer | 40 | 未披露 | 未持股 | 2026-03-12 |
董事简历
中英对照 | 中文 | 英文- Patrick Spangler
-
Patrick Spangler目前担任数字梦百合情报公司Vigilanz的首席财务官，并担任LifeSpace Communities的董事会成员。他曾帮助领导高性能的新兴成长型公司，以及大型上市公司。早些时候，斯潘格勒曾担任Healthland的执行Vice President和首席财务官，该公司是一家为危重医院市场提供服务的电子人力资源公司。他也曾担任the Point-of-Care Medical Applications供应商Epocrates的首席财务官，他曾于2011年帮助实现上市，最终被AthenaHealth公司收购。任职Epocrates公司之前，他曾担任EV3a血管疗法（于2005年上市，随后被Covidien公司收购）的首席财务官，以及医疗设备制造商Empi公司（被Encore Medical公司收购）的首席财务官。
Patrick Spangler joined the Company as a director in March 2018. Since October 2020 Mr. Spangler has served as Chief Financial Officer of On Target Laboratories, a developer of fluorescent markers to target and illuminate cancer during surgery. From March 2020 to September 2020 Mr. Spangler served as Chief Financial Officer of MHC Software, LLC, a supplier of document automation software to a variety of industries. Prior to MHC, Mr. Spangler served as Chief Financial Officer of VigiLanz Corporation, a digital healthcare intelligence firm, from September 2014 to October 2019; Chief Financial Officer of Healthland Inc., an EHR company serving the critical access hospital market, from August 2012 to August 2014; Senior Vice President and Chief Financial Officer of Epocrates, Inc., then a public company listed on Nasdaq and a point-of-care medical applications provider, from October 2010 to August 2012; Operating Partner and CFO Advisor of Three Fields Capital, a private equity and venture capital investment firm., from April 2010 to October 2010; Chief Financial Officer of HighJump Software, a global provider of supply chain management software., from June 2009 to April 2010; Senior Vice President and Chief Financial Officer of ev3 Inc., then a public company listed on NASDAQ and a global endovascular company focused on identifying and treating peripheral vascular disease, from March 2005 to January 2009; and Executive Vice President and Chief Financial Officer for EMPI Inc., a medical device manufacturer, from July 1997 to March 2005. Prior to joining EMPI Inc., Mr. Spangler served for over eleven years in various senior finance leadership positions at Medtronic, Inc. NYSE: MDT, a global medical device company, Mr. Spangler currently serves as a director of Lifespace Communities Inc, which owns and operates 15 CCRCs in eight states and houses more than 5100 residents., and previously served on the board of Urologix Inc then a public company and a leader in less invasive in office BPH treatments, from August 2010 to February 2016. - Patrick Spangler目前担任数字梦百合情报公司Vigilanz的首席财务官，并担任LifeSpace Communities的董事会成员。他曾帮助领导高性能的新兴成长型公司，以及大型上市公司。早些时候，斯潘格勒曾担任Healthland的执行Vice President和首席财务官，该公司是一家为危重医院市场提供服务的电子人力资源公司。他也曾担任the Point-of-Care Medical Applications供应商Epocrates的首席财务官，他曾于2011年帮助实现上市，最终被AthenaHealth公司收购。任职Epocrates公司之前，他曾担任EV3a血管疗法（于2005年上市，随后被Covidien公司收购）的首席财务官，以及医疗设备制造商Empi公司（被Encore Medical公司收购）的首席财务官。
- Patrick Spangler joined the Company as a director in March 2018. Since October 2020 Mr. Spangler has served as Chief Financial Officer of On Target Laboratories, a developer of fluorescent markers to target and illuminate cancer during surgery. From March 2020 to September 2020 Mr. Spangler served as Chief Financial Officer of MHC Software, LLC, a supplier of document automation software to a variety of industries. Prior to MHC, Mr. Spangler served as Chief Financial Officer of VigiLanz Corporation, a digital healthcare intelligence firm, from September 2014 to October 2019; Chief Financial Officer of Healthland Inc., an EHR company serving the critical access hospital market, from August 2012 to August 2014; Senior Vice President and Chief Financial Officer of Epocrates, Inc., then a public company listed on Nasdaq and a point-of-care medical applications provider, from October 2010 to August 2012; Operating Partner and CFO Advisor of Three Fields Capital, a private equity and venture capital investment firm., from April 2010 to October 2010; Chief Financial Officer of HighJump Software, a global provider of supply chain management software., from June 2009 to April 2010; Senior Vice President and Chief Financial Officer of ev3 Inc., then a public company listed on NASDAQ and a global endovascular company focused on identifying and treating peripheral vascular disease, from March 2005 to January 2009; and Executive Vice President and Chief Financial Officer for EMPI Inc., a medical device manufacturer, from July 1997 to March 2005. Prior to joining EMPI Inc., Mr. Spangler served for over eleven years in various senior finance leadership positions at Medtronic, Inc. NYSE: MDT, a global medical device company, Mr. Spangler currently serves as a director of Lifespace Communities Inc, which owns and operates 15 CCRCs in eight states and houses more than 5100 residents., and previously served on the board of Urologix Inc then a public company and a leader in less invasive in office BPH treatments, from August 2010 to February 2016.
- Lynn Vos
-
Lynn Vos自2017年10月起担任肌肉萎缩症协会主席兼首席执行官。在此之前，Vos女士自1994年以来一直担任GHG|GreyHealth Group的首席执行官，是利用数字能力改善公共卫生的倡导者。Vos女士还担任NTELOS Wireless（纳斯达克上市公司），JED Foundation（致力于保护大学生情绪健康的领先非营利组织）的董事会成员，并且是MMRF（先驱癌症研究基金会）的创始董事会成员。
Lynn Vos joined the Company as a director in 2015. Since November 2020 Ms. Vos has run VosHealth, LLC, a healthcare consulting firm focused on advising healthcare start-ups and marketing organizations. From October 2017 to November 2020 Ms. Vos served as the President and Chief Executive Officer of the Muscular Dystrophy Association. From October 1994 to September 2017 Ms. Vos served as the Chief Executive Officer of ghg | greyhealth group, a healthcare advertising and communications company. Ms. Vos currently serves as a director of Modular Medical OTCQB: MODD, a development stage medical device company focused on the design, development, and eventual commercialization of an innovative insulin pump. Ms. Vos previously served on the boards of nTelos Wireless, a wireless telecommunications company and PCS provider; the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college students; and was a founding board member of Multiple Myeloma Research Foundation (MMRF), a pioneering cancer research foundation. - Lynn Vos自2017年10月起担任肌肉萎缩症协会主席兼首席执行官。在此之前，Vos女士自1994年以来一直担任GHG|GreyHealth Group的首席执行官，是利用数字能力改善公共卫生的倡导者。Vos女士还担任NTELOS Wireless（纳斯达克上市公司），JED Foundation（致力于保护大学生情绪健康的领先非营利组织）的董事会成员，并且是MMRF（先驱癌症研究基金会）的创始董事会成员。
- Lynn Vos joined the Company as a director in 2015. Since November 2020 Ms. Vos has run VosHealth, LLC, a healthcare consulting firm focused on advising healthcare start-ups and marketing organizations. From October 2017 to November 2020 Ms. Vos served as the President and Chief Executive Officer of the Muscular Dystrophy Association. From October 1994 to September 2017 Ms. Vos served as the Chief Executive Officer of ghg | greyhealth group, a healthcare advertising and communications company. Ms. Vos currently serves as a director of Modular Medical OTCQB: MODD, a development stage medical device company focused on the design, development, and eventual commercialization of an innovative insulin pump. Ms. Vos previously served on the boards of nTelos Wireless, a wireless telecommunications company and PCS provider; the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college students; and was a founding board member of Multiple Myeloma Research Foundation (MMRF), a pioneering cancer research foundation.
- James Lang
-
James Lang自2023年起担任公司董事长，自2016年起担任公司董事。直到2025年，他担任生命科学行业领先的商业化服务公司EVERSANA的首席执行官（“CEO”），现在担任该公司的董事。在他创立EVERSANA的五年里，它现在的收入超过了10亿美元，在全球40个地点拥有7000多名员工。他曾担任Decision Resources Group（DRG）的首席执行官，他将该公司转变为一家领先的医疗数据和分析公司。在此之前，Jim是IHS剑桥能源研究协会（IHS CERA）的首席执行官，该公司是公认的能源行业订阅信息产品领导者，还曾担任全球领先的战略咨询公司Strategic Decisions Group（SDG）的总裁。朗先生以优异成绩获得新罕布什尔大学电气和计算机工程学士学位，并以优异成绩获得塔克商学院MBA学位。Jim Lang目前还在纳斯达克上市公司OptimizeRX（OPRX）和纳斯达克上市公司Halozyme Therapeutics, Inc.（HALO）担任董事。
James Lang has served as Chairman of the Board of Directors since 2023 and has served as the Company's director since 2016. Until 2025, he served as Chief Executive Officer ("CEO") of EVERSANA, the leading commercialization services company for the life sciences industry, where he now serves as a Director. In the five years since he founded EVERSANA, it is now over $1B in revenue, with more than 7,000 employees across 40 global locations. He formerly served as the CEO of Decision Resources Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy industry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School of Business. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company, and Halozyme Therapeutics, Inc. (HALO), a Nasdaq listed Company. - James Lang自2023年起担任公司董事长，自2016年起担任公司董事。直到2025年，他担任生命科学行业领先的商业化服务公司EVERSANA的首席执行官（“CEO”），现在担任该公司的董事。在他创立EVERSANA的五年里，它现在的收入超过了10亿美元，在全球40个地点拥有7000多名员工。他曾担任Decision Resources Group（DRG）的首席执行官，他将该公司转变为一家领先的医疗数据和分析公司。在此之前，Jim是IHS剑桥能源研究协会（IHS CERA）的首席执行官，该公司是公认的能源行业订阅信息产品领导者，还曾担任全球领先的战略咨询公司Strategic Decisions Group（SDG）的总裁。朗先生以优异成绩获得新罕布什尔大学电气和计算机工程学士学位，并以优异成绩获得塔克商学院MBA学位。Jim Lang目前还在纳斯达克上市公司OptimizeRX（OPRX）和纳斯达克上市公司Halozyme Therapeutics, Inc.（HALO）担任董事。
- James Lang has served as Chairman of the Board of Directors since 2023 and has served as the Company's director since 2016. Until 2025, he served as Chief Executive Officer ("CEO") of EVERSANA, the leading commercialization services company for the life sciences industry, where he now serves as a Director. In the five years since he founded EVERSANA, it is now over $1B in revenue, with more than 7,000 employees across 40 global locations. He formerly served as the CEO of Decision Resources Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy industry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School of Business. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company, and Halozyme Therapeutics, Inc. (HALO), a Nasdaq listed Company.
- Gregory D. Wasson
-
Gregory D. Wasson于2020年7月加入Optimizerx Corp.公司，担任董事。自2016年1月以来，Wasson先生一直担任Wasson Enterprise的总裁和联合创始人。Wasson Enterprise是一家家族理财办公室，致力于建立可持续、高增长的企业。2015年1月，Wasson先生担任Walgreens Boots Alliance，Inc.的总裁兼首席执行官。Walgreens Boots Alliance，Inc.是一家以制药为主导的全球健康和福利企业。在被任命为合并公司Walgreens Boots Alliance的总裁和首席执行官之前，Wasson先生在Walgreens担任了多个职责和行政领导职位，包括2009年至2015年担任总裁和首席执行官，2007年至2009年担任总裁兼首席运营官，2001年至2006年担任Walgreen Health Services总裁兼执行副总裁，1999年至2001年担任门店运营副总裁，1986年至1999年担任地区经理，1981年至1986年担任药房技术员、药剂师和门店经理。Wasson先生目前担任Foresight Acquisition Corp.Nasdaq：FORE（一家特殊目的收购公司）的董事长，并在以下私营公司的董事会任职：Dom's Kitchen and Market、Truvian、Reliefband、Golden Fleece Beverages，Inc.，iA、Performance Health Systems、Cooler Screens，Inc.，Innventure.Gregory D。Wasson是Walgreens-Boots-Alliance，Inc.的前总裁兼首席执行官，Walgreens-Boots-Alliance，Inc.是全球第一家以制药为主导的健康和福利企业。从2009年到2014年，他是Walgreen公司的董事、总裁和首席执行官。他是一名注册药剂师，1980年加入Walgreen，担任多个职责职位，包括Walgreen Health Initiaties总裁、高级副总裁、执行副总裁、总裁和首席运营官。Wasson先生自2015年7月起担任PNC Financial Services Group，Inc.董事会成员，在过去的五年中，他曾担任Walgreen Co.和AmerisourceBergen Corporation董事会成员。
Gregory D. Wasson joined the Company as a director in July 2020. Since January 2016 Mr. Wasson has served as President and Co-founder of Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses. In January 2015 Mr. Wasson served as President and Chief Executive Officer of Walgreens Boots Alliance, Inc., a global, pharmacy-led health and wellbeing enterprise. Prior to being appointed President and Chief Executive Officer of the combined companies, Walgreens Boots Alliance, Mr. Wasson rose through the ranks through a number of positions of increasing responsibility and executive leadership at Walgreens including, from 2009 to 2015 as its President and Chief Executive Officer, from 2007 to 2009 as its President and Chief Operating Officer, from 2001 to 2006 as the President and Executive Vice President of Walgreen Health Services, from 1999 to 2001 as its Vice President of Store Operations, from 1986 to 1999 as a District Manager, and from 1981 to 1986 as a Pharmacy Technician, Pharmacist and Store Manager. Mr. Wasson currently serves as the Chairman of Foresight Acquisition Corp. Nasdaq: FORE, a special purpose acquisition company, and on the boards of the following privately held companies: Dom's Kitchen and Market, Truvian, Reliefband, Golden Fleece Beverages, Inc., iA, Performance Health Systems, Cooler Screens, Inc., Innventure.Gregory D. Wasson is the former President and Chief Executive Officer of Walgreens Boots Alliance, Inc., the first global pharmacy-led health and wellbeing enterprise. From 2009 through 2014 he was Director, President and Chief Executive Officer of Walgreen Co. A registered pharmacist, he joined Walgreen in 1980 and served in a number of positions of responsibility, including President of Walgreens Health Initiatives, Senior Vice President, Executive Vice President, and President and Chief Operating Officer. Mr. Wasson has served on the board of The PNC Financial Services Group, Inc. since July 2015 and, in the past five years, he has served on the boards of Walgreen Co. and AmerisourceBergen Corporation. - Gregory D. Wasson于2020年7月加入Optimizerx Corp.公司，担任董事。自2016年1月以来，Wasson先生一直担任Wasson Enterprise的总裁和联合创始人。Wasson Enterprise是一家家族理财办公室，致力于建立可持续、高增长的企业。2015年1月，Wasson先生担任Walgreens Boots Alliance，Inc.的总裁兼首席执行官。Walgreens Boots Alliance，Inc.是一家以制药为主导的全球健康和福利企业。在被任命为合并公司Walgreens Boots Alliance的总裁和首席执行官之前，Wasson先生在Walgreens担任了多个职责和行政领导职位，包括2009年至2015年担任总裁和首席执行官，2007年至2009年担任总裁兼首席运营官，2001年至2006年担任Walgreen Health Services总裁兼执行副总裁，1999年至2001年担任门店运营副总裁，1986年至1999年担任地区经理，1981年至1986年担任药房技术员、药剂师和门店经理。Wasson先生目前担任Foresight Acquisition Corp.Nasdaq：FORE（一家特殊目的收购公司）的董事长，并在以下私营公司的董事会任职：Dom's Kitchen and Market、Truvian、Reliefband、Golden Fleece Beverages，Inc.，iA、Performance Health Systems、Cooler Screens，Inc.，Innventure.Gregory D。Wasson是Walgreens-Boots-Alliance，Inc.的前总裁兼首席执行官，Walgreens-Boots-Alliance，Inc.是全球第一家以制药为主导的健康和福利企业。从2009年到2014年，他是Walgreen公司的董事、总裁和首席执行官。他是一名注册药剂师，1980年加入Walgreen，担任多个职责职位，包括Walgreen Health Initiaties总裁、高级副总裁、执行副总裁、总裁和首席运营官。Wasson先生自2015年7月起担任PNC Financial Services Group，Inc.董事会成员，在过去的五年中，他曾担任Walgreen Co.和AmerisourceBergen Corporation董事会成员。
- Gregory D. Wasson joined the Company as a director in July 2020. Since January 2016 Mr. Wasson has served as President and Co-founder of Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses. In January 2015 Mr. Wasson served as President and Chief Executive Officer of Walgreens Boots Alliance, Inc., a global, pharmacy-led health and wellbeing enterprise. Prior to being appointed President and Chief Executive Officer of the combined companies, Walgreens Boots Alliance, Mr. Wasson rose through the ranks through a number of positions of increasing responsibility and executive leadership at Walgreens including, from 2009 to 2015 as its President and Chief Executive Officer, from 2007 to 2009 as its President and Chief Operating Officer, from 2001 to 2006 as the President and Executive Vice President of Walgreen Health Services, from 1999 to 2001 as its Vice President of Store Operations, from 1986 to 1999 as a District Manager, and from 1981 to 1986 as a Pharmacy Technician, Pharmacist and Store Manager. Mr. Wasson currently serves as the Chairman of Foresight Acquisition Corp. Nasdaq: FORE, a special purpose acquisition company, and on the boards of the following privately held companies: Dom's Kitchen and Market, Truvian, Reliefband, Golden Fleece Beverages, Inc., iA, Performance Health Systems, Cooler Screens, Inc., Innventure.Gregory D. Wasson is the former President and Chief Executive Officer of Walgreens Boots Alliance, Inc., the first global pharmacy-led health and wellbeing enterprise. From 2009 through 2014 he was Director, President and Chief Executive Officer of Walgreen Co. A registered pharmacist, he joined Walgreen in 1980 and served in a number of positions of responsibility, including President of Walgreens Health Initiatives, Senior Vice President, Executive Vice President, and President and Chief Operating Officer. Mr. Wasson has served on the board of The PNC Financial Services Group, Inc. since July 2015 and, in the past five years, he has served on the boards of Walgreen Co. and AmerisourceBergen Corporation.
- Catherine M. Klema
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Stephen L. Silvestro
StephenL.Silvestro于2019年4月29日加入公司担任首席商务官。Silvestro先生从2018年1月至加入我们之前一直在CCH&174；Tagetik担任其Vice President兼总经理。Silvestro先生于2017年4月至2018年1月在Prognos担任首席商务官，在此之前，他于2007年9月至2017年4月在Decision Resources Group担任多个职位，最后一次担任执行Vice President，全球销售主管。除了上面提到的，Silvestro先生不持有并且在过去五年中未在任何具有根据《交易法》第12条或《交易法》第15D条的要求注册的证券类别的公司或任何注册的公司中担任任何其他董事职务作为1940年《投资公司法》下的投资公司。
Stephen L. Silvestro was appointed the Chief Executive Officer in March 2025, after having served as Interim Chief Executive Officer commencing in January 2025. He joined the Company as Chief Commercial Officer in April 2019 and has since served as President from October 2023 until his appointment as interim Chief Executive Officer. Prior to joining the Company, Mr. Silvestro was with CCH Tagetik, a Wolters Klur company that provides corporate performance management software solutions for planning, consolidation and reporting, as its Vice President and General Manager from January 2018 until April 2019. From April 2017 to January 2018, Mr. Silvestro was with Prognos Health, Inc., a healthcare data and analytics company, as its Chief Commercial Officer and, before that, from September 2007 to April 2017, he was with Decision Resces Group, a multi national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in vario capacities with him last serving as Executive Vice President, Head of Global Sales.- StephenL.Silvestro于2019年4月29日加入公司担任首席商务官。Silvestro先生从2018年1月至加入我们之前一直在CCH&174；Tagetik担任其Vice President兼总经理。Silvestro先生于2017年4月至2018年1月在Prognos担任首席商务官，在此之前，他于2007年9月至2017年4月在Decision Resources Group担任多个职位，最后一次担任执行Vice President，全球销售主管。除了上面提到的，Silvestro先生不持有并且在过去五年中未在任何具有根据《交易法》第12条或《交易法》第15D条的要求注册的证券类别的公司或任何注册的公司中担任任何其他董事职务作为1940年《投资公司法》下的投资公司。
- Stephen L. Silvestro was appointed the Chief Executive Officer in March 2025, after having served as Interim Chief Executive Officer commencing in January 2025. He joined the Company as Chief Commercial Officer in April 2019 and has since served as President from October 2023 until his appointment as interim Chief Executive Officer. Prior to joining the Company, Mr. Silvestro was with CCH Tagetik, a Wolters Klur company that provides corporate performance management software solutions for planning, consolidation and reporting, as its Vice President and General Manager from January 2018 until April 2019. From April 2017 to January 2018, Mr. Silvestro was with Prognos Health, Inc., a healthcare data and analytics company, as its Chief Commercial Officer and, before that, from September 2007 to April 2017, he was with Decision Resces Group, a multi national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in vario capacities with him last serving as Executive Vice President, Head of Global Sales.
- Marion Odence Ford
Marion Odence Ford于2021年2月加入公司担任总法律顾问兼首席合规官。从2013年4月到2020年6月，Odence-Ford女士担任Decision Resources Group的副总裁兼副总法律顾问，这是一家跨国公司，为制药，生物技术，医疗设备，医疗保健提供商和付款人以及管理式护理公司提供高价值的全球数据解决方案，分析和咨询服务。从2004年11月到2012年11月，Odence-Ford女士担任CRAInternational，Inc.DBA Charles River Associates的副总裁兼副总法律顾问，这是一家全球性的咨询公司，为世界各地的主要律师事务所、公司、会计师事务所和政府提供经济、金融和战略专业知识。从2004年5月到2004年11月，Odence-Ford女士是GTC Law Group，LLP的成员，这是一家专门从事高科技和生物技术行业公司业务的律师事务所。加入GTC Law Group之前，Odence-Ford从2002年11月到2004年5月在美国银行公司/Fleet Boston Financial Corporation法律团队工作，从1999年10月到2002年11月在阿卡迈技术有限公司工作。Odence-Ford女士的法律职业生涯始于Mintz，Levin，Cohn，Ferris，Glovsky和Popeo，PC的私人执业，在那里她为上市公司和私人公司提供公司事务建议。
Marion Odence Ford was named the Chief Legal & Administrative Officer in August 2025. She joined the Company as General Counsel & Chief Compliance Officer in February 2021 and was appointed the Chief Legal Officer & Chief Human Resces Officer in January 2025, a position she held until her appointment as Chief Legal & Administrative Officer. From April 2013 to June 2020, Ms. Odence Ford was Vice President & Deputy General Counsel at Decision Resces Group, a multi national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies. From November 2004 to November 2012, Ms. Odence Ford was Vice President & Associate General Counsel at CRA International, Inc. (d/b/a Charles River Associates), a global consulting firm that offers economic, financial, and strategic expertise to major law firms, corporations, accounting firms, and governments around the world. From May 2004 to November 2004, Ms. Odence Ford was a member of the GTC Law Group, LLP, a law firm specializing in the biness affairs of companies in the high tech and biotech indtries. Prior to joining the GTC Law Group, Ms. Odence Ford worked on the legal teams of Bank of America Corporation/Fleet Boston Financial Corporation from November 2002 to May 2004, and Akamai Technologies, Inc. from October 1999 to November 2002. Ms. Odence Ford began her legal career in private practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate matters.- Marion Odence Ford于2021年2月加入公司担任总法律顾问兼首席合规官。从2013年4月到2020年6月，Odence-Ford女士担任Decision Resources Group的副总裁兼副总法律顾问，这是一家跨国公司，为制药，生物技术，医疗设备，医疗保健提供商和付款人以及管理式护理公司提供高价值的全球数据解决方案，分析和咨询服务。从2004年11月到2012年11月，Odence-Ford女士担任CRAInternational，Inc.DBA Charles River Associates的副总裁兼副总法律顾问，这是一家全球性的咨询公司，为世界各地的主要律师事务所、公司、会计师事务所和政府提供经济、金融和战略专业知识。从2004年5月到2004年11月，Odence-Ford女士是GTC Law Group，LLP的成员，这是一家专门从事高科技和生物技术行业公司业务的律师事务所。加入GTC Law Group之前，Odence-Ford从2002年11月到2004年5月在美国银行公司/Fleet Boston Financial Corporation法律团队工作，从1999年10月到2002年11月在阿卡迈技术有限公司工作。Odence-Ford女士的法律职业生涯始于Mintz，Levin，Cohn，Ferris，Glovsky和Popeo，PC的私人执业，在那里她为上市公司和私人公司提供公司事务建议。
- Marion Odence Ford was named the Chief Legal & Administrative Officer in August 2025. She joined the Company as General Counsel & Chief Compliance Officer in February 2021 and was appointed the Chief Legal Officer & Chief Human Resces Officer in January 2025, a position she held until her appointment as Chief Legal & Administrative Officer. From April 2013 to June 2020, Ms. Odence Ford was Vice President & Deputy General Counsel at Decision Resces Group, a multi national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies. From November 2004 to November 2012, Ms. Odence Ford was Vice President & Associate General Counsel at CRA International, Inc. (d/b/a Charles River Associates), a global consulting firm that offers economic, financial, and strategic expertise to major law firms, corporations, accounting firms, and governments around the world. From May 2004 to November 2004, Ms. Odence Ford was a member of the GTC Law Group, LLP, a law firm specializing in the biness affairs of companies in the high tech and biotech indtries. Prior to joining the GTC Law Group, Ms. Odence Ford worked on the legal teams of Bank of America Corporation/Fleet Boston Financial Corporation from November 2002 to May 2004, and Akamai Technologies, Inc. from October 1999 to November 2002. Ms. Odence Ford began her legal career in private practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate matters.
- Brendan Merrell
Brendan Merrell，最近担任公司客户战略与项目管理高级副总裁。在担任这一职务之前，Merrell先生在公司的商业运营部门担任过多个职位，包括高级副总裁、客户战略和高级副总裁、患者参与。在加入公司之前，2011年7月至2020年2月，Merrell先生在Decision Resources Group（“DRG”）任职，该公司是一家跨国企业，为制药、生物技术、医疗器械、医疗保健提供者和付款人以及管理式医疗公司提供高价值的全球数据解决方案、分析和咨询服务，最后担任商业卓越主管。
Brendan Merrell was named the Chief Operating Officer in Augt 2025. He joined the Company in February 2020 and has held vario progressive senior management positions within commercial operations, including most recently serving as the Company's Senior VP, Client Strategy and Program Management from October 2023 through Augt 2025, Senior VP, Client Strategy from October 2021 through October 2023 and Senior VP, Patient Engagement from February 2020 through October 2021. Prior to joining the Company, from July 2011 through February 2020, Mr. Merrell was at Decision Resces Group, a multi national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in vario capacities with him last serving as Head of Commercial Excellence.- Brendan Merrell，最近担任公司客户战略与项目管理高级副总裁。在担任这一职务之前，Merrell先生在公司的商业运营部门担任过多个职位，包括高级副总裁、客户战略和高级副总裁、患者参与。在加入公司之前，2011年7月至2020年2月，Merrell先生在Decision Resources Group（“DRG”）任职，该公司是一家跨国企业，为制药、生物技术、医疗器械、医疗保健提供者和付款人以及管理式医疗公司提供高价值的全球数据解决方案、分析和咨询服务，最后担任商业卓越主管。
- Brendan Merrell was named the Chief Operating Officer in Augt 2025. He joined the Company in February 2020 and has held vario progressive senior management positions within commercial operations, including most recently serving as the Company's Senior VP, Client Strategy and Program Management from October 2023 through Augt 2025, Senior VP, Client Strategy from October 2021 through October 2023 and Senior VP, Patient Engagement from February 2020 through October 2021. Prior to joining the Company, from July 2011 through February 2020, Mr. Merrell was at Decision Resces Group, a multi national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in vario capacities with him last serving as Head of Commercial Excellence.
- Edward Stelmakh
Edward Stelmakh于2025年8月被任命为首席财务与战略官。他于2021年10月加入公司担任首席财务官兼首席运营官，在此之前一直担任该职位，直至被任命为首席财务与战略官。在加入公司之前，Stelmakh先生自2020年4月起担任日本全球医疗保健企业的一个部门Otsuka America Pharmaceuticals Inc.（“Otsuka”）的高级副总裁、首席财务官和首席运营官。Previoly，曾在Otsuka担任多个职位，包括高级副总裁兼首席财务官（2017年12月– 2020年3月）以及副总裁兼首席财务官（2015年12月– 2017年11月）。2010年3月至2015年12月，Stelmakh先生在LabCorp，Inc.的一个部门Covance工作，担任财务、临床开发和商业化服务副总裁。在此之前，Stelmakh先生曾在强生、赛诺菲安万特、欧加隆/先灵葆雅和迈兰担任过多个职责日益增加的职位。
Edward Stelmakh was named the Chief Financial & Strategy Officer in August 2025. He joined the Company as Chief Financial Officer & Chief Operations Officer in October 2021, a position he held until his appointment as Chief Financial & Strategy Officer. Prior to joining the Company, Mr. Stelmakh served as Senior VP, Chief Financial Officer and Chief Operating Officer of Otsuka America Pharmaceuticals Inc. ("Otsuka"), a division of a Japanese global healthcare enterprise, since April 2020. Previoly, he held vario positions at Otsuka including Senior Vice President and Chief Financial Officer (December 2017 – March 2020) and Vice President and Chief Financial Officer (December 2015 – November 2017). From March 2010 to December 2015, Mr. Stelmakh worked at Covance, a division of LabCorp, Inc., as Vice President, Finance, Clinical Development and Commercialization Services. Prior thereto, Mr. Stelmakh held a variety of positions of increasing responsibilities at Johnson & Johnson, Sanofi Aventis, Organon/Schering Plough and Mylan.- Edward Stelmakh于2025年8月被任命为首席财务与战略官。他于2021年10月加入公司担任首席财务官兼首席运营官，在此之前一直担任该职位，直至被任命为首席财务与战略官。在加入公司之前，Stelmakh先生自2020年4月起担任日本全球医疗保健企业的一个部门Otsuka America Pharmaceuticals Inc.（“Otsuka”）的高级副总裁、首席财务官和首席运营官。Previoly，曾在Otsuka担任多个职位，包括高级副总裁兼首席财务官（2017年12月– 2020年3月）以及副总裁兼首席财务官（2015年12月– 2017年11月）。2010年3月至2015年12月，Stelmakh先生在LabCorp，Inc.的一个部门Covance工作，担任财务、临床开发和商业化服务副总裁。在此之前，Stelmakh先生曾在强生、赛诺菲安万特、欧加隆/先灵葆雅和迈兰担任过多个职责日益增加的职位。
- Edward Stelmakh was named the Chief Financial & Strategy Officer in August 2025. He joined the Company as Chief Financial Officer & Chief Operations Officer in October 2021, a position he held until his appointment as Chief Financial & Strategy Officer. Prior to joining the Company, Mr. Stelmakh served as Senior VP, Chief Financial Officer and Chief Operating Officer of Otsuka America Pharmaceuticals Inc. ("Otsuka"), a division of a Japanese global healthcare enterprise, since April 2020. Previoly, he held vario positions at Otsuka including Senior Vice President and Chief Financial Officer (December 2017 – March 2020) and Vice President and Chief Financial Officer (December 2015 – November 2017). From March 2010 to December 2015, Mr. Stelmakh worked at Covance, a division of LabCorp, Inc., as Vice President, Finance, Clinical Development and Commercialization Services. Prior thereto, Mr. Stelmakh held a variety of positions of increasing responsibilities at Johnson & Johnson, Sanofi Aventis, Organon/Schering Plough and Mylan.
- Theresa Greco
特蕾莎·格雷科于2023年10月加入公司，担任公司首席商务官，公司收购了Healthy Offers，Inc.（“Medicx Health”），格雷科女士于2022年8月至2023年10月担任该公司总裁。在加入Medicx Health之前，Greco女士于2018年8月至2022年1月在医疗保健数据和分析公司Prognos Health，Inc.担任首席商务官，领导产品战略、营销、销售和CTomer交付的各个方面。在加入Prognos之前，Greco女士在MediSpend担任首席商务官职位，MediSpend是一家专注于生命科学合规解决方案的全球科技公司。从2010年8月到2017年8月，Greco女士通过收购Health Market Science在LexisNexis Healthcare任职，在那里她担任过各种进步的高管职位，包括在CTomer Success、产品战略、商业战略和销售方面，这些领域促进了收入增长和盈利能力，从而成功退出。Greco女士于2008年4月至2010年8月期间在美国计算机科学公司领导生命科学咨询集团，为生命科学公司的主数据管理提供咨询和技术解决方案。在2008年之前，Greco女士曾在艾昆纬和辉瑞担任过多个职位。
Theresa Greco joined the Company in October 2023 as the Company's Chief Commercial Officer with the Company's acquisition of Healthy Offers, Inc. ("Medicx Health"), where Ms. Greco served as its President from August 2022 through October 2023. Prior to joining Medicx Health, Ms. Greco was at Prognos Health, Inc., a healthcare data and analytics company, from August 2018 to January 2022 as its Chief Commercial Officer where she led all aspects of product strategy, marketing, sales, and ctomer delivery. Prior to Prognos, Ms. Greco held the Chief Commercial Officer position at MediSpend, a global technology company focused on life sciences compliance solutions. From August 2010 through August 2017, Ms. Greco was with LexisNexis Healthcare through their acquisition of Health Market Science, where she held a variety of progressive executive positions including in Ctomer Success, Product Strategy, Commercial Strategy, and Sales that contributed to revenue growth and profitability that yielded a successful exit. Ms. Greco led the Life Sciences consulting group providing consultation and technology solutions to life sciences companies for master data management at Computer Sciences Corporation from April 2008 to August 2010. Prior to 2008, Ms. Greco held vario positions at IQVIA and Pfizer.- 特蕾莎·格雷科于2023年10月加入公司，担任公司首席商务官，公司收购了Healthy Offers，Inc.（“Medicx Health”），格雷科女士于2022年8月至2023年10月担任该公司总裁。在加入Medicx Health之前，Greco女士于2018年8月至2022年1月在医疗保健数据和分析公司Prognos Health，Inc.担任首席商务官，领导产品战略、营销、销售和CTomer交付的各个方面。在加入Prognos之前，Greco女士在MediSpend担任首席商务官职位，MediSpend是一家专注于生命科学合规解决方案的全球科技公司。从2010年8月到2017年8月，Greco女士通过收购Health Market Science在LexisNexis Healthcare任职，在那里她担任过各种进步的高管职位，包括在CTomer Success、产品战略、商业战略和销售方面，这些领域促进了收入增长和盈利能力，从而成功退出。Greco女士于2008年4月至2010年8月期间在美国计算机科学公司领导生命科学咨询集团，为生命科学公司的主数据管理提供咨询和技术解决方案。在2008年之前，Greco女士曾在艾昆纬和辉瑞担任过多个职位。
- Theresa Greco joined the Company in October 2023 as the Company's Chief Commercial Officer with the Company's acquisition of Healthy Offers, Inc. ("Medicx Health"), where Ms. Greco served as its President from August 2022 through October 2023. Prior to joining Medicx Health, Ms. Greco was at Prognos Health, Inc., a healthcare data and analytics company, from August 2018 to January 2022 as its Chief Commercial Officer where she led all aspects of product strategy, marketing, sales, and ctomer delivery. Prior to Prognos, Ms. Greco held the Chief Commercial Officer position at MediSpend, a global technology company focused on life sciences compliance solutions. From August 2010 through August 2017, Ms. Greco was with LexisNexis Healthcare through their acquisition of Health Market Science, where she held a variety of progressive executive positions including in Ctomer Success, Product Strategy, Commercial Strategy, and Sales that contributed to revenue growth and profitability that yielded a successful exit. Ms. Greco led the Life Sciences consulting group providing consultation and technology solutions to life sciences companies for master data management at Computer Sciences Corporation from April 2008 to August 2010. Prior to 2008, Ms. Greco held vario positions at IQVIA and Pfizer.
- Doug Besch
Doug Besch于2025年1月被任命为首席产品与技术官。他于2021年5月加入公司，担任产品战略与创新高级副总裁，并于2022年10月成为公司首席产品官。在加入公司之前，2018年1月至2021年5月，Besch博士担任科睿唯安（previoly Decision Resces Group（“DRG”））的Payor和市场准入解决方案副总裁，该公司是一家跨国企业，为制药、生物技术、医疗器械、医疗保健提供者和付款人以及管理式医疗公司提供高价值的全球数据解决方案、分析和咨询服务。在加入科睿唯安之前，从2012年1月到2017年6月，Besch博士是RX Savings Solutions的联合创始人和首席产品官，该公司通过结合临床技术、透明度、会员参与和礼宾支持，帮助会员和付款人降低处方药成本。在加入RXSavings Solutions之前，Besch博士于2007年至2013年在沃尔格林联合博姿公司担任药剂师。
Doug Besch was named the Chief Product & Technology Officer in January 2025. He joined the Company in May 2021 as Senior VP Product Strategy & Innovation and became the Company's Chief Product Officer in October 2022. Prior to joining the Company, from January 2018 to May 2021, Dr. Besch was the Vice President over Payor and Market Access Solutions for Clarivate (previoly Decision Resces Group ("DRG")), a multi national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies. Prior to Clarivate, from January 2012 to June 2017, Dr. Besch was a co founder and the Chief Product Officer for Rx Savings Solutions, a company which helps members and payers reduce prescription drug costs through a combination of clinical technology, transparency, member engagement and concierge support. Prior to RxSavings Solutions, Dr. Besch practiced as a pharmacist for the Walgreens Boots Alliance corporation from 2007 through 2013.- Doug Besch于2025年1月被任命为首席产品与技术官。他于2021年5月加入公司，担任产品战略与创新高级副总裁，并于2022年10月成为公司首席产品官。在加入公司之前，2018年1月至2021年5月，Besch博士担任科睿唯安（previoly Decision Resces Group（“DRG”））的Payor和市场准入解决方案副总裁，该公司是一家跨国企业，为制药、生物技术、医疗器械、医疗保健提供者和付款人以及管理式医疗公司提供高价值的全球数据解决方案、分析和咨询服务。在加入科睿唯安之前，从2012年1月到2017年6月，Besch博士是RX Savings Solutions的联合创始人和首席产品官，该公司通过结合临床技术、透明度、会员参与和礼宾支持，帮助会员和付款人降低处方药成本。在加入RXSavings Solutions之前，Besch博士于2007年至2013年在沃尔格林联合博姿公司担任药剂师。
- Doug Besch was named the Chief Product & Technology Officer in January 2025. He joined the Company in May 2021 as Senior VP Product Strategy & Innovation and became the Company's Chief Product Officer in October 2022. Prior to joining the Company, from January 2018 to May 2021, Dr. Besch was the Vice President over Payor and Market Access Solutions for Clarivate (previoly Decision Resces Group ("DRG")), a multi national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies. Prior to Clarivate, from January 2012 to June 2017, Dr. Besch was a co founder and the Chief Product Officer for Rx Savings Solutions, a company which helps members and payers reduce prescription drug costs through a combination of clinical technology, transparency, member engagement and concierge support. Prior to RxSavings Solutions, Dr. Besch practiced as a pharmacist for the Walgreens Boots Alliance corporation from 2007 through 2013.
- Andrew D Silva
Andrew D Silva于2021年9月加入公司，目前担任公司首席商务官，在公司财务战略、资本分配、投资者关系、企业发展、长期规划等方面与执行领导团队和董事会密切合作。在担任这一职务之前，从2021年9月到2025年8月，D'Silva先生担任公司企业财务高级副总裁，负责监督财务规划和分析以及投资者关系。在加入公司之前，2016年8月至2021年8月，D'Silva先生在提供全方位服务的中间市场投资银行B. Riley证券担任高级医疗保健研究分析师，专注于覆盖医疗保健领域公司的股票研究。2012年9月至2016年8月，他担任资历不断增加的股票研究职务，最终被任命为投资银行公司Merriman Capital，Inc.的董事总经理，专注于覆盖中小型公司的股票研究。
Andrew D Silva joined the Company in September 2021, and currently serves as the Company's Chief Business Officer, working closely with the executive leadership team and the Board on the Company's financial strategy, capital allocation, investor relations, corporate development, and long range planning. Prior to this role, from September 2021 through August 2025,Mr. D'Silva served as the Company's SVP, Corporate Finance, overseeing financial planning and analysis and investor relations. Prior to joining the Company, from August 2016 through August 2021, Mr. D'Silva was a Senior Healthcare Research Analyst, focusing on equity research covering companies in the healthcare sector, at B. Riley Securities, a full service, middle market investment bank and, from September 2012 through August 2016, he held equity research roles of increasing seniority culminating in his appointment as Managing Director, focusing on equity research covering small and mid cap companies, at Merriman Capital, Inc., an investment banking firm.- Andrew D Silva于2021年9月加入公司，目前担任公司首席商务官，在公司财务战略、资本分配、投资者关系、企业发展、长期规划等方面与执行领导团队和董事会密切合作。在担任这一职务之前，从2021年9月到2025年8月，D'Silva先生担任公司企业财务高级副总裁，负责监督财务规划和分析以及投资者关系。在加入公司之前，2016年8月至2021年8月，D'Silva先生在提供全方位服务的中间市场投资银行B. Riley证券担任高级医疗保健研究分析师，专注于覆盖医疗保健领域公司的股票研究。2012年9月至2016年8月，他担任资历不断增加的股票研究职务，最终被任命为投资银行公司Merriman Capital，Inc.的董事总经理，专注于覆盖中小型公司的股票研究。
- Andrew D Silva joined the Company in September 2021, and currently serves as the Company's Chief Business Officer, working closely with the executive leadership team and the Board on the Company's financial strategy, capital allocation, investor relations, corporate development, and long range planning. Prior to this role, from September 2021 through August 2025,Mr. D'Silva served as the Company's SVP, Corporate Finance, overseeing financial planning and analysis and investor relations. Prior to joining the Company, from August 2016 through August 2021, Mr. D'Silva was a Senior Healthcare Research Analyst, focusing on equity research covering companies in the healthcare sector, at B. Riley Securities, a full service, middle market investment bank and, from September 2012 through August 2016, he held equity research roles of increasing seniority culminating in his appointment as Managing Director, focusing on equity research covering small and mid cap companies, at Merriman Capital, Inc., an investment banking firm.